Syn­ovo GmbH

Syn­ovo is involved in anti-inflam­mat­ory and immun­osup­press­ive drug optim­iz­a­tion pro­jects on behalf of cli­ents from the phar­ma­ceut­ic­al industry. In col­lab­or­a­tion with pub­lic labor­at­or­ies, Syn­ovo also improves exist­ing tech­no­lo­gies for the devel­op­ment of new drugs from pro­teins and nuc­le­ic acids.

The com­pany’s focus is to offer vari­ous test­ing meth­ods and mod­els for the selec­tion of drug can­did­ates with improved absorp­tion, dis­pos­i­tion, meta­bol­ism and elim­in­a­tion (ADME or DMPK) prop­er­ties. Wherever pos­sible, these para­met­ers are determ­ined using human cells, pro­teins or sys­tems to ensure the rel­ev­ance of the data in case of human application.